The multiple-ascending-dose study that preceded phase 2

Published 24 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Urva and colleagues published a phase 1b, multicentre, double-blind, placebo-controlled, multiple-ascending-dose trial of LY3437943 in people with type 2 diabetes in The Lancet in 2022. Its purpose was safety, tolerability and pharmacokinetics across escalating exposure over 12 weeks, with glycaemic and weight measures as exploratory outcomes.

What phase 1b asks

Before dose-response can be studied in a larger population, a compound's tolerability at escalating exposure and its pharmacokinetics in the target population have to be characterised. That is what a multiple-ascending-dose study does: successive cohorts receive higher exposures while safety is monitored.

Efficacy measures in such a study are exploratory. They inform the design of phase 2; they are not the evidence phase 2 later provides.

What was reported

The compound's half-life, measured in days, supported the administration interval used in all subsequent trials. Adverse events were predominantly gastrointestinal and dose-related. Reductions in glycated haemoglobin and body weight were observed and reported as exploratory findings.

The paper is the pharmacokinetic foundation the phase 2 programme was built on.

Reading early-phase work correctly

Small, short, and designed around safety. Quoting a phase 1b weight figure as evidence of efficacy misreads the trial's purpose; the authors frame it as supporting progression.

Where a page cites retatrutide data without naming the phase, this is the distinction it has dropped.

Supply

Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Retatrutide Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

What phase 1b asks?

Before dose-response can be studied in a larger population, a compound's tolerability at escalating exposure and its pharmacokinetics in the target population have to be characterised. That is what a multiple-ascending-dose study does: successive cohorts receive higher exposures while safety is monitored.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Retatrutide Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.